Success of Lexaria’s Human Clinical Hypertension Study Sparks 19% Increase in Premarket Stock Price

Company achieves major milestone with potential to address $96bn market

Lexaria Bioscience Corp. (Nasdaq:LEXX), a global innovator in drug delivery platforms, today shared the news of its successful human clinical study HYPER-H21-4 and the market responded: The company’s premarket stock price rose a notable 19 percent. With exceptional safety and tolerability results, the recent study showed a sustained drop in blood pressure in patients with active hypertension after five weeks of taking an oral cannabidiol or CBD therapy, using Lexaria’s patented DehydraTECHTM-CBD capsule formulation.

The HYPER-H21-4 study achieved its safety and efficacy objectives while lowering blood pressure for both patients currently taking other antihypertensive drugs and those not taking other targeted medications. Zero adverse events were reported in the study. Thanks to the efficiency of Lexaria’s DehydraTECH technology, the notable decrease in blood pressure was achieved with low doses of the CBD therapy.

“That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “DehydraTECH also demonstrated excellent safety and tolerability results and no adverse changes in liver enzymes throughout the study.”

The standout study leads the way in reducing blood pressure when compared with other published research. Lexaria is now preparing for its upcoming Phase Ib Investigational New Drug clinical study to be registered with the U.S. Food and Drug Administration.

HYPER-H21-4 was a randomized, double-blinded, placebo-controlled, cross-over study that consisted of 66 male and female volunteers between the ages of 40-70. The complete protocol is now available at PubMed.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Success of Lexaria’s Human Clinical Hypertension Study Sparks 19% Increase in Premarket Stock Price

Editor Prism MarketView